Compounding group sues FDA for removing Lilly's weight loss drug from shortage list
A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s blockbuster weight loss and diabetes drugs off its list of medicines in short supply last week.
Forty years after the Hatch-Waxman Act created a market for affordable generic versions of prescription medications, ...
The Food and Drug Administration (FDA) on Friday declared shortages of three intravenous drugs produced at a North Carolina ...
After securing FDA approval, they produce and sell these drugs to distributors ... would offer GPOs bonus payments from Medicare for taking steps to prevent drug shortages, such as signing ...
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...
The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...
Drug shortages that happen when demand surges can ... as compounded drugs are not FDA-approved and could have inconsistent potency. The FDA has issued warnings about the risks of compounded ...
Hurricane Helene damaged one of the major NC-based manufacturing facilities of IV fluids. What’s being done to help hospitals ...
A trade group representing compounding pharmacies sued the FDA for a “reckless and arbitrary” decision to remove Eli Lilly's ...
The shortage of pediatric cancer drugs is a growing concern for families and healthcare providers, with critical medications, like injectable methotrexate and leucovrin, increasingly hard to obtain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback